Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. - Wikidata - wikimedia - TriplyDB

Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene.

Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene.

http://www.wikidata.org/entity/Q33865182

about

The RNA Splicing Response to DNA Damage Splicing Regulation: A Molecular Device to Enhance Cancer Cell Adaptation Posttranscriptional Regulation of Splicing Factor SRSF1 and Its Role in Cancer Cell Biology Splicing Regulators and Their Roles in Cancer Biology and Therapy Splice isoforms as therapeutic targets for colorectal cancer Defective control of pre-messenger RNA splicing in human disease The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged Regulation of Mcl-1 by SRSF1 and SRSF5 in cancer cells The role of mRNA splicing in prostate cancer.Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer.Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events.Complex alternative splicing of the smarca2 gene suggests the importance of smarca2-B variants Alternative RNA splicing and cancer Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA construct.Regulation of chemoresistance via alternative messenger RNA splicing Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer Mechanisms of the androgen receptor splicing in prostate cancer cells.Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.Beyond GWASs: illuminating the dark road from association to function The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival.The AR dependent cell cycle: mechanisms and cancer relevance.Alternative splicing programs in prostate cancer.RNA splicing: a new player in the DNA damage response Hallmarks of alternative splicing in cancer.Deregulation of splicing factors and breast cancer development.Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems.The importance of p53 pathway genetics in inherited and somatic cancer genomes.Alternative splicing and cell survival: from tissue homeostasis to disease.Cyclin D1, cancer progression, and opportunities in cancer treatment.Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.Downregulation of splicing factor SRSF3 induces p53β, an alternatively spliced isoform of p53 that promotes cellular senescence.Analysis of in vivo Interaction between RNA Binding Proteins and Their RNA Targets by UV Cross-linking and Immunoprecipitation (CLIP) Method.miR‑30c suppresses prostate cancer survival by targeting the ASF/SF2 splicing factor oncoprotein.Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.Alternative Splicing as a Target for Cancer Treatment.CCND1 rs9344 polymorphisms are associated with the genetic susceptibility to cervical cancer in Chinese population.Disruption by SaCas9 Endonuclease of HERV-K, a Retroviral Gene with Oncogenic and Neuropathogenic Potential, Inhibits Molecules Involved in Cancer and Amyotrophic Lateral Sclerosis

P2860

Q26777046-4494B28E-A22D-440D-8CD2-E207EF81A1EA Q26798148-F488050F-6F79-4AF7-897B-26E209B8C03A Q26798154-EE6745BD-06CD-4DCA-9D31-12320ED31609 Q26798158-62256509-8480-4104-B2EF-53D8D8F65341 Q27006500-8DA4C0D9-0985-496F-823D-1A6C757AA899 Q28077564-5D7734E9-DB16-4890-B4D0-FCB2F7127BE9 Q28083838-158581C7-5C92-4E05-B87C-9BCB9F6096F4 Q28297381-7C4D3EFC-A600-4C89-BCFD-438B01B554FB Q28484403-A4F5C103-DA99-4036-8804-5495CC21F555 Q33922376-10D67BB9-EF1F-4364-AD37-20CBB9033166 Q34040857-F5569E27-193B-4EA8-A6A4-4040ED047477 Q34240895-A3F1F9ED-A80F-46CF-B96F-250061F7E89D Q35142978-4BD89E64-9AD7-4DA7-BF9A-6EFE8C4A93A1 Q35589667-7BEC8364-4B27-42B9-8615-0D3D02CAC326 Q35730604-FA61AF56-E0C1-44BE-942C-C8FC82CB8BE0 Q35822883-FAC71025-BEB0-493E-9472-BD702D845A31 Q35993683-34DF6064-5E94-46B6-8687-683FB3A1CB71 Q36005683-AA6DB8F7-B6FC-45EE-B0CC-95AB9FAA9698 Q36497254-EB27D3B4-9435-497C-9CDD-CDED18BF738B Q37298148-B399A745-033A-4F59-B86B-BCCEBC5CCEEE Q37631845-0D06EDB9-63BB-4D0C-B2D1-42F0C47477C2 Q37904028-8B934BFB-001F-46DC-9778-9D6BB8671CEF Q38132132-1D8723B9-DF12-4F8E-A12A-01D721B1E975 Q38155497-F03AF100-CE8B-4066-B523-5E62B723A44D Q38171229-ED4ACB45-9CF3-431A-95C1-6044B7BBC8F5 Q38463397-7036DFC5-24AE-418D-AF00-1FAF3DE902D9 Q38735423-4A152F92-F692-49C0-8D5B-5A79A2343EAB Q38786667-68016024-7232-4EB1-90BD-B90088C11105 Q38968877-1B16147C-A595-4804-9E10-E494B63CFFB0 Q38970431-D09F0CE3-7963-4A1B-8BA3-88BBCDC80E3E Q39063150-A6DB3CFC-2D67-44F3-9D91-A636AFC79FEF Q39317407-FB6F3C91-3B90-40CA-97F6-9394809E42CA Q42238703-C2049490-ED4B-40D4-8BDB-26F173B09216 Q42546726-5EBEEFFE-9A80-4394-9E60-238E92BF405C Q47784889-C5C6B888-4021-436A-A159-EB630AEB6985 Q49519966-2DA65E20-7AC3-4851-8833-E9B1AFBC1A9F Q50033988-C558F625-2163-4BD6-BE85-9D7C3DCB1D45 Q53286766-C0990756-EDCA-441B-A09A-450B1DC52068 Q58796885-7B0F1076-0B68-4FEA-8448-2BF8154AA56A

P2860

Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene.

http://www.wikidata.org/entity/Q33865182

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Identification of ASF/SF2 as a ...... or of the cyclin D1b oncogene.

@ast

Identification of ASF/SF2 as a ...... or of the cyclin D1b oncogene.

@en

type

label

Identification of ASF/SF2 as a ...... or of the cyclin D1b oncogene.

@ast

Identification of ASF/SF2 as a ...... or of the cyclin D1b oncogene.

@en

prefLabel

Identification of ASF/SF2 as a ...... or of the cyclin D1b oncogene.

@ast

Identification of ASF/SF2 as a ...... or of the cyclin D1b oncogene.

@en

P1433

Q33865182-A0AA0674-75DD-4138-A0EA-79F1032F1B83

P1476

Q33865182-FBFB7AA9-D9DA-4AEF-A6AA-C90E4F07D473

P2093

Q33865182-09A6B1C8-E510-4FCC-B337-BC50B6CDCA26

Q33865182-590A8F15-2D76-42F8-8C0B-05434300D771

Q33865182-A57B9100-526A-4B80-A745-96BCC0969DAE

Q33865182-BEBCECCA-18F1-4707-9F76-00E7265A6471

Q33865182-C2D27E7B-D326-4E88-B268-4C789ED7AA71

Q33865182-D9D7E256-EAF0-4E91-8416-9E6BB8755A7D

P2860

Q33865182-0C1619D6-09E9-4807-B23F-ADB58BA1F919

Q33865182-0EBEF2C0-C348-49F4-92E4-FA4B1307A03D

Q33865182-0FB4C8B3-FFCA-4350-9862-9FF2CC16A4E7

Q33865182-1D0ABBA6-2239-46A0-AAD6-67B6AEA5047B

Q33865182-26B5CF53-DAF0-42AA-BC60-13BDDB9EB1DA

Q33865182-328DF91A-B567-4F58-98E4-DECD9C1F8BEF

Q33865182-338B121D-4830-4C20-8E6F-DF5D414EDDB6

Q33865182-34CA65C6-2AB4-443E-8BAF-11C13EBE04FC

Q33865182-35E9F894-FDCB-4BB6-8029-A91F116A4187

Q33865182-397FB240-4D87-429E-91B7-AD1D6F65358B

P304

Q33865182-1A3CFC36-574C-40F6-A456-57C4CA308174

P31

Q33865182-900748E8-12D6-4ADA-8E5F-A122C45A37EF

P356

Q33865182-47677C94-0DB2-4547-95F6-7CC4DE3F42B3

P407

Q33865182-C1BD3C90-A855-4BFD-98F8-F49E5815CDE1

P433

Q33865182-28609FD0-B384-4BD8-A192-100EB760FB43

P478

Q33865182-B756CAC9-DCB9-4E20-B641-068FA6245510

P50

Q33865182-0FD4F90E-1C11-49FE-ACA2-1F32CF95BC96

Q33865182-362C6FA5-8216-4CF3-A4F2-0771D7A43B5B

Q33865182-DABE0BC3-C749-4F06-ABCE-219C81DFBF98

P577

Q33865182-96FD895B-9CED-40F7-8D9C-00B0ACB872F6

P698

Q33865182-107C67E5-DDDD-4E0A-8E21-FC970B9287A4

P932

Q33865182-38014979-FDCF-41AE-B0BF-350FD6DAB7EC

P356

0008-5472.CAN-09-3468

P1433

Cancer Research

P1476

Identification of ASF/SF2 as a ...... or of the cyclin D1b oncogene.

@en

P2093

Clay E S Comstock

http://www.w3.org/2001/XMLSchema#string

Linda M Parysek

http://www.w3.org/2001/XMLSchema#string

Matthew J Schiewer

http://www.w3.org/2001/XMLSchema#string

Michael A Augello

http://www.w3.org/2001/XMLSchema#string

Nicholas A Olshavsky

http://www.w3.org/2001/XMLSchema#string

Terry Hyslop

http://www.w3.org/2001/XMLSchema#string

P2860

Hypophosphorylated ASF/SF2 binds TAP and is present in messenger ribonucleoproteins

The human SWI/SNF subunit Brm is a regulator of alternative splicing

INFECTION OF HUMAN AND SIMIAN TISSUE CULTURES WITH ROUS SARCOMA VIRUS

SR proteins in vertical integration of gene expression from transcription to RNA processing to translation

The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x

High-efficiency transformation of mammalian cells by plasmid DNA

Mechanisms of alternative pre-messenger RNA splicing

A central domain of cyclin D1 mediates nuclear receptor corepressor activity

ESEfinder: A web resource to identify exonic splicing enhancers

The biology of chromatin remodeling complexes

P304

3975-3984

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-3468

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Karen E Knudsen

P577

2010-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20460515

http://www.w3.org/2001/XMLSchema#string

P932

2873684

http://www.w3.org/2001/XMLSchema#string